Managing  ||| S:0 E:9 ||| VBG
hyponatremia  ||| S:9 E:22 ||| NN
in  ||| S:22 E:25 ||| IN
patients  ||| S:25 E:34 ||| NNS
with  ||| S:34 E:39 ||| IN
heart  ||| S:39 E:45 ||| NN
failure  ||| S:45 E:53 ||| NN
Approximately  ||| S:53 E:67 ||| RB
20 ||| S:67 E:69 ||| CD
%  ||| S:69 E:71 ||| NN
of  ||| S:71 E:74 ||| IN
heart  ||| S:74 E:80 ||| NN
failure  ||| S:80 E:88 ||| NN
patients  ||| S:88 E:97 ||| NNS
have  ||| S:97 E:102 ||| VBP
low  ||| S:102 E:106 ||| JJ
levels  ||| S:106 E:113 ||| NNS
of  ||| S:113 E:116 ||| IN
serum  ||| S:116 E:122 ||| JJ
sodium ||| S:122 E:128 ||| NN
,  ||| S:128 E:130 ||| ,
often  ||| S:130 E:136 ||| RB
at  ||| S:136 E:139 ||| IN
a  ||| S:139 E:141 ||| DT
time  ||| S:141 E:146 ||| NN
when  ||| S:146 E:151 ||| WRB
they  ||| S:151 E:156 ||| PRP
are  ||| S:156 E:160 ||| VBP
hospitalized  ||| S:160 E:173 ||| VBN
during  ||| S:173 E:180 ||| IN
a  ||| S:180 E:182 ||| DT
period  ||| S:182 E:189 ||| NN
of  ||| S:189 E:192 ||| IN
decompensation ||| S:192 E:206 ||| NN
.  ||| S:206 E:208 ||| .
The  ||| S:208 E:212 ||| DT
presence  ||| S:212 E:221 ||| NN
of  ||| S:221 E:224 ||| IN
hyponatremia  ||| S:224 E:237 ||| JJ
adversely  ||| S:237 E:247 ||| NN
affects  ||| S:247 E:255 ||| VBZ
outcomes  ||| S:255 E:264 ||| VBN
in  ||| S:264 E:267 ||| IN
heart  ||| S:267 E:273 ||| NN
failure  ||| S:273 E:281 ||| NN
and  ||| S:281 E:285 ||| CC
is  ||| S:285 E:288 ||| VBZ
associated  ||| S:288 E:299 ||| VBN
with  ||| S:299 E:304 ||| IN
impaired  ||| S:304 E:313 ||| JJ
cognitive  ||| S:313 E:323 ||| NN
and  ||| S:323 E:327 ||| CC
neuromuscular  ||| S:327 E:341 ||| JJ
function ||| S:341 E:349 ||| NN
.  ||| S:349 E:351 ||| .
Current  ||| S:351 E:359 ||| JJ
strategies  ||| S:359 E:370 ||| NNS
for  ||| S:370 E:374 ||| IN
treating  ||| S:374 E:383 ||| VBG
hyponatremia  ||| S:383 E:396 ||| NN
in  ||| S:396 E:399 ||| IN
heart  ||| S:399 E:405 ||| NN
failure  ||| S:405 E:413 ||| NN
patients  ||| S:413 E:422 ||| NNS
have  ||| S:422 E:427 ||| VBP
limited  ||| S:427 E:435 ||| JJ
efficacy ||| S:435 E:443 ||| NN
.  ||| S:443 E:445 ||| .
Although  ||| S:445 E:454 ||| IN
the  ||| S:454 E:458 ||| DT
development  ||| S:458 E:470 ||| NN
of  ||| S:470 E:473 ||| IN
hyponatremia  ||| S:473 E:486 ||| NN
in  ||| S:486 E:489 ||| IN
heart  ||| S:489 E:495 ||| NN
failure  ||| S:495 E:503 ||| NN
patients  ||| S:503 E:512 ||| NNS
is  ||| S:512 E:515 ||| VBZ
polyfactorial ||| S:515 E:528 ||| VBN
,  ||| S:528 E:530 ||| ,
the  ||| S:530 E:534 ||| DT
nonosmotic  ||| S:534 E:545 ||| JJ
release  ||| S:545 E:553 ||| NN
of  ||| S:553 E:556 ||| IN
arginine  ||| S:556 E:565 ||| JJ
vasopressin  ||| S:565 E:577 ||| NNS
( ||| S:577 E:578 ||| -LRB-
AVP ||| S:578 E:581 ||| NNP
)  ||| S:581 E:583 ||| -RRB-
from  ||| S:583 E:588 ||| IN
the  ||| S:588 E:592 ||| DT
posterior  ||| S:592 E:602 ||| JJ
pituitary  ||| S:602 E:612 ||| NN
plays  ||| S:612 E:618 ||| VBZ
a  ||| S:618 E:620 ||| DT
dominant  ||| S:620 E:629 ||| JJ
role  ||| S:629 E:634 ||| NN
in  ||| S:634 E:637 ||| IN
this  ||| S:637 E:642 ||| DT
process  ||| S:642 E:650 ||| NN
through  ||| S:650 E:658 ||| IN
its  ||| S:658 E:662 ||| PRP$
effects  ||| S:662 E:670 ||| NNS
on  ||| S:670 E:673 ||| IN
regulating  ||| S:673 E:684 ||| VBG
the  ||| S:684 E:688 ||| DT
absorption  ||| S:688 E:699 ||| NN
of  ||| S:699 E:702 ||| IN
free  ||| S:702 E:707 ||| JJ
water  ||| S:707 E:713 ||| NN
in  ||| S:713 E:716 ||| IN
the  ||| S:716 E:720 ||| DT
distal  ||| S:720 E:727 ||| JJ
portion  ||| S:727 E:735 ||| NN
of  ||| S:735 E:738 ||| IN
the  ||| S:738 E:742 ||| DT
nephron ||| S:742 E:749 ||| NN
.  ||| S:749 E:751 ||| .
Drugs  ||| S:751 E:757 ||| NNS
which  ||| S:757 E:763 ||| WDT
block  ||| S:763 E:769 ||| VBP
the  ||| S:769 E:773 ||| DT
effects  ||| S:773 E:781 ||| NNS
of  ||| S:781 E:784 ||| IN
AVP  ||| S:784 E:788 ||| NNP
on  ||| S:788 E:791 ||| IN
the  ||| S:791 E:795 ||| DT
V2  ||| S:795 E:798 ||| CD
receptor  ||| S:798 E:807 ||| NNS
have  ||| S:807 E:812 ||| VBP
been  ||| S:812 E:817 ||| VBN
shown  ||| S:817 E:823 ||| VBN
to  ||| S:823 E:826 ||| TO
increase  ||| S:826 E:835 ||| VB
serum  ||| S:835 E:841 ||| JJ
sodium  ||| S:841 E:848 ||| NN
by  ||| S:848 E:851 ||| IN
promoting  ||| S:851 E:861 ||| VBG
the  ||| S:861 E:865 ||| DT
excretion  ||| S:865 E:875 ||| NN
of  ||| S:875 E:878 ||| IN
free  ||| S:878 E:883 ||| JJ
water  ||| S:883 E:889 ||| NN
from  ||| S:889 E:894 ||| IN
the  ||| S:894 E:898 ||| DT
kidney ||| S:898 E:904 ||| NN
.  ||| S:904 E:906 ||| .
In  ||| S:906 E:909 ||| IN
this  ||| S:909 E:914 ||| DT
review ||| S:914 E:920 ||| NN
,  ||| S:920 E:922 ||| ,
the  ||| S:922 E:926 ||| DT
theoretical  ||| S:926 E:938 ||| JJ
basis  ||| S:938 E:944 ||| NN
supporting  ||| S:944 E:955 ||| VBG
the  ||| S:955 E:959 ||| DT
use  ||| S:959 E:963 ||| NN
of  ||| S:963 E:966 ||| IN
AVP  ||| S:966 E:970 ||| NNP
blockers  ||| S:970 E:979 ||| NN
is  ||| S:979 E:982 ||| VBZ
discussed  ||| S:982 E:992 ||| VBN
and  ||| S:992 E:996 ||| CC
results  ||| S:996 E:1004 ||| NNS
from  ||| S:1004 E:1009 ||| IN
clinical  ||| S:1009 E:1018 ||| JJ
trials  ||| S:1018 E:1025 ||| NNS
in  ||| S:1025 E:1028 ||| IN
which  ||| S:1028 E:1034 ||| WDT
they  ||| S:1034 E:1039 ||| PRP
were  ||| S:1039 E:1044 ||| VBD
administered  ||| S:1044 E:1057 ||| VBN
to  ||| S:1057 E:1060 ||| TO
euvolemic  ||| S:1060 E:1070 ||| VB
and  ||| S:1070 E:1074 ||| CC
hypervolemic  ||| S:1074 E:1087 ||| JJ
patients  ||| S:1087 E:1096 ||| NNS
are  ||| S:1096 E:1100 ||| VBP
reviewed ||| S:1100 E:1108 ||| VBN
.  ||| S:1108 E:1110 ||| .
Administration  ||| S:1110 E:1125 ||| NN
of  ||| S:1125 E:1128 ||| IN
AVP  ||| S:1128 E:1132 ||| NNP
blockers  ||| S:1132 E:1141 ||| VBD
to  ||| S:1141 E:1144 ||| TO
heart  ||| S:1144 E:1150 ||| NN
failure  ||| S:1150 E:1158 ||| NN
patients  ||| S:1158 E:1167 ||| NNS
increases  ||| S:1167 E:1177 ||| VBZ
free  ||| S:1177 E:1182 ||| JJ
water  ||| S:1182 E:1188 ||| NN
excretion ||| S:1188 E:1197 ||| NN
,  ||| S:1197 E:1199 ||| ,
promotes  ||| S:1199 E:1208 ||| JJ
weight  ||| S:1208 E:1215 ||| NN
loss ||| S:1215 E:1219 ||| NN
,  ||| S:1219 E:1221 ||| ,
and  ||| S:1221 E:1225 ||| CC
increases  ||| S:1225 E:1235 ||| NNS
serum  ||| S:1235 E:1241 ||| VBP
sodium  ||| S:1241 E:1248 ||| JJ
levels  ||| S:1248 E:1255 ||| NNS
without  ||| S:1255 E:1263 ||| IN
significant  ||| S:1263 E:1275 ||| JJ
major  ||| S:1275 E:1281 ||| JJ
adverse  ||| S:1281 E:1289 ||| JJ
effects ||| S:1289 E:1296 ||| NNS
.  ||| S:1296 E:1298 ||| .
Clinical  ||| S:1298 E:1307 ||| JJ
trial  ||| S:1307 E:1313 ||| NN
results  ||| S:1313 E:1321 ||| NNS
demonstrate  ||| S:1321 E:1333 ||| VBP
safety  ||| S:1333 E:1340 ||| NN
during  ||| S:1340 E:1347 ||| IN
long-term  ||| S:1347 E:1357 ||| JJ
administration ||| S:1357 E:1371 ||| NN
.  ||| S:1371 E:1373 ||| .
These  ||| S:1373 E:1379 ||| DT
findings  ||| S:1379 E:1388 ||| NNS
indicate  ||| S:1388 E:1397 ||| VBP
that  ||| S:1397 E:1402 ||| IN
the  ||| S:1402 E:1406 ||| DT
use  ||| S:1406 E:1410 ||| NN
of  ||| S:1410 E:1413 ||| IN
AVP  ||| S:1413 E:1417 ||| NNP
receptor  ||| S:1417 E:1426 ||| NN
antagonists  ||| S:1426 E:1438 ||| NNS
should  ||| S:1438 E:1445 ||| MD
be  ||| S:1445 E:1448 ||| VB
considered  ||| S:1448 E:1459 ||| VBN
in  ||| S:1459 E:1462 ||| IN
heart  ||| S:1462 E:1468 ||| NN
failure  ||| S:1468 E:1476 ||| NN
patients  ||| S:1476 E:1485 ||| NNS
who  ||| S:1485 E:1489 ||| WP
have  ||| S:1489 E:1494 ||| VBP
evidence  ||| S:1494 E:1503 ||| NN
of  ||| S:1503 E:1506 ||| IN
significant  ||| S:1506 E:1518 ||| JJ
hyponatremia ||| S:1518 E:1530 ||| NN
.  ||| S:1530 E:1532 ||| .
